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SUMMARY
Plasminogen activator inhibitor-1 (PAI-1) paradoxically enhances tumor progression and angiogenesis;
however, the mechanism supporting this role is not known. Here we provide evidence that PAI-1 is essential
to protect endothelial cells (ECs) from FasL-mediated apoptosis. In the absence of host-derived PAI-1, hu-
man neuroblastoma cells implanted in PAI-1-deficient mice form smaller and poorly vascularized tumors
containing an increased number of apoptotic ECs. We observed that knockdown of PAI-1 in ECs enhances
cell-associated plasmin activity and increases spontaneous apoptosis in vitro. We further demonstrate that
plasmin cleaves FasL at Arg144-Lys145, releasing a soluble proapoptotic FasL fragment from the surface of
ECs. The data provide a mechanism explaining the proangiogenic activity of PAI-1.INTRODUCTION
Angiogenesis, the process leading to the formation of new blood
vessels, plays a central role in solid tumor growth andmetastatic
dissemination (Carmeliet, 2003). This process requires a coordi-
nated and temporal regulation of adhesive, proteolytic, and
migratory events. During angiogenesis, endothelial cells (ECs)
stimulated by hypoxia and angiogenic factors leave a state of
quiescence to proliferate and migrate through the extracellular
matrix (ECM). During this process, ECs become more sensitive
to apoptosis (Folkman, 2003). The Fas/FasL pathway is a key
mediator of EC apoptosis and controls angiogenesis. The ex-
pression of Fas and FasL is upregulated in activated ECs and
upon EC detachment, hypoxia, or exposure to vascular endothe-
lial growth factor (VEGF) (Bouchet et al., 2002; Cardier et al.,
1999; Chavakis and Dimmeler, 2002). Natural inhibitors of angio-
genesis like thrombospondin 1 (TSP1) and pigment epithelium-
derived factor (PEDF) derive their specific antiangiogenic func-tion from upregulating FasL and enhancing apoptosis in ECs
(Volpert et al., 2002). The ability of ECs to become resistant to
Fas-mediated apoptosis is therefore critical for angiogenesis to
succeed. Among the known mechanisms of resistance is EC at-
tachment to the ECM,whichmodulates Fas-mediated apoptosis
by downregulating Fas and upregulating c-Flip, an endogenous
antagonist of caspase-8 (Aoudjit and Vuori, 2000, 2001). How-
ever, beyond this mechanism, little is known of other potential
ways for ECs to escape.
During angiogenesis, ECs express and activate enzymes that
degrade the ECMas they invade surrounding tissues. Stimulated
ECs produce urokinase-type plasminogen activator (uPA), which
converts plasminogen into its active form, plasmin (Pepper,
2001). uPA itself is secreted as an inactive precursor form (pro-
uPA) that binds with high affinity to a specific cell surface glyco-
sylphosphatidylinositol-anchored receptor designated uPAR
(Blasi and Verde, 1990). When activated, uPAR-bound uPA en-
hances the generation of plasmin at the cell surface, promotingSIGNIFICANCE
Plasminogen activator inhibitor-1 (PAI-1), the central regulator of plasmin generation, is a predictor of poor clinical outcome
in cancer patients.We previously reported that PAI-1 has a proangiogenic function, but themechanism has remained poorly
understood. Here we describe a mechanism for the proangiogenic function of PAI-1 by providing evidence that PAI-1 pro-
tects endothelial cells (ECs) against Fas/FasL-mediated apoptosis. We demonstrate that in the absence of PAI-1 in ECs,
there is an increase in plasmin generation and the release by plasmin of a soluble FasL fragment. This plasmin-generated
soluble FasL activates Fas and is a potent inducer of apoptosis in ECs. Our results suggest that PAI-1 could be a target for
antiangiogenic and antivascular therapies.
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Plasmin Cleaves FasL and Induces ApoptosisFigure 1. Absence of Host-Derived PAI-1 Reduces
Human Neuroblastoma Tumor Growth and Angiogen-
esis
(A) Representative neuroblastoma tumors collected 6 weeks
after orthotopic implantation in PAI-1+/+Rag-1/ or PAI-1/
Rag-1/ mice.
(B) Tumor volume in PAI-1+/+ (n = 6–8) and PAI-1/ (n = 6–8)
mice over time. The data represent means ± standard devia-
tion (SD).
(C) Representative images of fluorescence angiographies ob-
tained 3weeks after tumor implantation. Tumor cells are EGFP
positive (green), and blood vessels (red) are recognized by the
presence of the biotinylated tomato lectin-Texas red avidin D
complex.
(D) Representative microphotographs of tumor sections
stained for PECAM-1/CD31 4 weeks after tumor implantation.
(E) Microvessel area valueswere determined in tumor sections
stained for PECAM-1/CD31 at the indicated time points as de-
scribed in Chantrain et al. (2004). The data represent means ±
SD of 6 sections examined in each of 6–8 tumors per time
point.
*p < 0.05, **p < 0.01 in (B) and (E). Scale bars = 100 mm in (C)
and (D).ECM degradation, the activation of matrix metalloproteinases
(MMPs), and the release and activation of ECM- and cell sur-
face-anchored growth factors (Dano et al., 2005). Plasminogen
activator inhibitor-1 (PAI-1) is the physiological inhibitor of uPA
and therefore controls the activation of plasminogen into plas-
min. In addition to interacting with uPA, PAI-1 also binds to vitro-
nectin. The binding of PAI-1 to vitronectin results in its stabiliza-
tion but also interferes with the binding of integrins of the av
family to the RGD domain of vitronectin and therefore with cell
migration (Deng et al., 1996). The two inhibitory functions of
PAI-1 in proteolysis and in cell attachment initially led to the pre-
diction that PAI-1 would have an antiangiogenic function. It was
therefore surprising to discover that high rather than low levels of
PAI-1 were predictive of poor outcome in patients suffering from
several types of cancers like breast, colon, and neuroblastoma
(Foekens et al., 1995; Ganesh et al., 1994; Sugiura et al.,
1999). Consistent with a positive effect of PAI-1 on cancer pro-
gression, we and others have published data providing some
explanation for the paradoxical effect of PAI-1 in cancer. We
demonstrated that in the absence of host-derived PAI-1, there
is a defect of tumor vascularization in mice implanted subcuta-
neously with transformed keratinocytes (Bajou et al., 1998,
2001) and that this is related to the antiproteolytic activity of
PAI-1. The effect of PAI-1 on angiogenesis is dose dependent,
with a stimulatory role reported at low physiological concentra-
tions and an inhibitory role at pharmacological concentrations
(Bajou et al., 2004). The exact mechanism by which inhibition
of proteolysis by PAI-1 promotes angiogenesis, however, has
not been determined. Here we provide evidence for such
a mechanism by demonstrating that PAI-1 expression by ECs
is critical to protect them against FasL-mediated apoptosis.
RESULTS
Absence of Host-Derived PAI-1 Reduces Human
Neuroblastoma Tumor Growth and Angiogenesis
To investigate the importance of PAI-1 in tumor progression, we
took advantage of the fact that neuroblastoma cells do notproduce PAI-1 (Sugiura et al., 1999) by orthotopically implanting
fragments from human SK-N-BE(2) neuroblastoma tumors
grown subcutaneously in the adrenal gland of PAI-1+/+Rag-1/
mice and PAI-1/Rag-1/ mice. The growth of these tumors
was monitored by sacrificing mice 3, 4, 5, 6, and 9 weeks after
implantation; measuring the tumor volume; and examining the
tumors for vascularization, malignant cell proliferation, and apo-
ptosis. We observed a significant difference in the tumor volume
between the two groups of mice, with the presence of much
smaller tumors in PAI-1/ mice compared with PAI-1+/+ mice
at weeks 5 and 6 after implantation (Figures 1A and 1B). By
week 6, all tumor-bearing PAI-1+/+ mice had to be sacrificed
due to the presence of large tumors (average volume 5 cm3).
However, by week 9 postimplantation, PAI-1/mice had devel-
oped tumors of size similar to those of PAI-1+/+ mice at week 6.
Because PAI-1 has been shown to play a regulatory role in angio-
genesis, the vasculature of these xenotransplanted tumors was
specifically examined. This analysis revealed a delay in the for-
mation of the vasculature between weeks 3 and 6 in tumors
derived from PAI-1/ mice compared with tumors derived
from PAI-1+/+ mice as indicated by angiographies (Figure 1C)
andmeasurements of themicrovessel area in tumor sections im-
munostained for the platelet/endothelial cell adhesion molecule-
1 (PECAM-1)/CD31 antigen (Figures 1D and 1E). At week 9, the
meanmicrovessel area of tumors fromPAI-1/micewas similar
to values observed in tumors from PAI-1+/+ mice at week 6. The
inhibition of angiogenesis in tumors derived from PAI-1/ mice
was associated with an inhibition of tumor cell proliferation as
indicated by a lower percentage of BrdU-positive tumor cells be-
tween weeks 3 and 5 (see Figures S1A and S1B available online).
In contrast, the presence or absence ofPAI-1 in host cells did not
affect tumor cell apoptosis (Figures S1C and S1D). However, we
observed a higher percentage of apoptotic ECs in tumors ob-
tained from PAI-1/ mice at weeks 3 and 4 after tumor implan-
tation when compared to tumors implanted in PAI-1+/+ mice
(Figures S1E and S1F). This increase in apoptotic ECs was not
observed in tumors obtained at weeks 5 and 6 after implantation.
The data thus indicate that in the absence of host-derived PAI-1,
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angiogenesis and an increase in EC apoptosis. These point to
a possible protective effect of PAI-1 against EC apoptosis.
PAI-1 Protects Endothelial Cells against Apoptosis
To test this possibility, we examined the effect of downregulation
of PAI-1 expression on apoptosis in human brain microvascular
ECs (HBMECs) using small interfering RNA (siRNA). Transfection
of HBMECs with a PAI-1 siRNA inhibited the expression of PAI-1
protein in cell extracts and conditioned media by 80% 72 hr after
transfection compared with untransfected cells or cells trans-
fected with a control scrambled siRNA (Figure 2A). Inhibition of
PAI-1 expression in HBMECs transfected with PAI-1 siRNA
was associated with a 5-fold increase in spontaneous apoptosis
(Figure 2B). Depending on the conditions, an 8- to 9-fold increase
in apoptosis was observed in other experiments. A 9-fold in-
crease in apoptosis was also documented when another PAI-1
siRNA sequence was tested (data not shown). Consistent with
this effect being the result of an inhibition of PAI-1 production
and secretion in the culturemedium, the percentage of apoptotic
HBMECs decreased by 40% with the addition of 0.25 mg/ml of
stable recombinant PAI-1 (rPAI-1) to the culture medium and
decreased to baseline levels at a concentration of 2.5 mg/ml.
The induction of HBMEC apoptosis upon PAI-1 downregulation
was associated with a 2-fold increase in caspase-3 activity com-
Figure 2. PAI-1 Protects Endothelial Cells from Apoptosis
(A) The levels of PAI-1 in conditionedmedium and in cell extracts of endothelial
cells (ECs) transfected with different siRNAs were measured by ELISA. The
data represent the means ± SD of triplicate samples.
(B) The percentage of apoptotic ECs was determined 72 hr after siRNA trans-
fection by TUNEL assay. rPAI-1 (0.25 and 2.5 mg/ml) was added 24 hr after
transfection. The data represent the means ± SD of triplicate samples.
(C) Caspase-3 activity in the experimental conditions described in (B) was
determined by colorimetric assay as described in Experimental Procedures.
The data represent the means ± SD of triplicate samples.
(D) PARP cleavage was examined by western blot analysis in the same exper-
imental conditions as in (B). rPAI-1 was added at 2.5 mg/ml 24 hr after siRNA
transfection.
*p < 0.01 versus control (CTL) siRNA; #p < 0.05, ##p < 0.01 compared to PAI-1
siRNA in (B) and (C).
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ure 2C) and was also associated with the detection of poly-
(ADP-ribose) polymerase (PARP) cleavage products by western
blot analysis (Figure 2D). These two effects were suppressed
by the additionof exogenous rPAI-1. Altogether, thedata suggest
that PAI-1 has a protective effect against spontaneous apoptosis
in ECs that is associated with an inhibition of caspase-3
activation.
uPA-Mediated Plasminogen Activation
Induces Apoptosis in HBMECs
To determine whether this protective effect against apoptosis
involves the antiproteolytic activity of PAI-1, we first examined
whether downregulation of PAI-1 affects the expression of uPA
and its receptor uPAR by western blot analysis. The data (Fig-
ure 3A) revealed higher levels of cell-associated uPA and uPAR
in HBMECs transfected with PAI-1 siRNA. The addition of stable
rPAI-1 to HBMECs transfected with PAI-1 siRNA decreased the
amount of cell-associated uPA, although not uPAR. Changes in
uPAR levelswere not associatedwith changes in uPAR transcrip-
tion sincewedidnot observechanges inuPARmRNAuponPAI-1
downregulation by RT-PCR (Figure 3A, lower panel). When bind-
ing to uPA, PAI-1 promotes the internalization of a uPA/uPAR/
PAI-1 complex, which results in an initial decrease in the expres-
sion of uPAR at the cell surface (Nykjaer et al., 1997). Consis-
tently, analysis by flow cytometry revealed an increase in cell
surface expression of uPA and uPAR in HBMECs upon downre-
gulation of PAI-1 that reflects a decrease in internalization of the
uPA/uPAR complex in the absence of PAI-1 (Figure 3B). Downre-
gulation of PAI-1 was also associated with higher levels of uPA-
associated proteolytic activity in cell extracts and conditioned
media that were not observed upon addition of rPAI-1 or a func-
tion-blocking antibody against the proteolytic activity of uPA
(Figure 3C). As anticipated and documented by casein zymogra-
phy, higher levels of cell-associated uPA activity in HBMECs
transfected with PAI-1 siRNA resulted in an increase in plasmin-
ogen activation, which was suppressed in the presence of stable
rPAI-1 (Figure 3D) or an anti-uPA antibody (data not shown).
Thus, the data indicate that PAI-1 controls the proteolytic activity
of uPA at the surface of ECs not only through inhibition of uPA
activity but also through inhibition of uPA and uPAR expression.
This raises the question of whether the protective effect of PAI-
1 against HBMEC apoptosis can be a direct consequence of
the antiproteolytic effect of PAI-1 on uPA and the subsequent
decrease in plasmin generation, or, in other words, whether there
is a causal link between EC apoptosis and cell-associated plas-
min activity. To test this possibility, we examined the effect of
blocking uPA and plasmin activity on apoptosis in HBMECs
transfected with PAI-1 siRNA. This experiment indicated a sup-
pression of spontaneous apoptosis in PAI-1-deficient HBMECs
in the presence of an antibody against the proteolytic function
of uPA, but not in the presence of a control normal IgG. There
was also a significant decrease in apoptosis in the presence of
aprotinin or when plasminogen was depleted from the serum in
the culture medium. The data thus confirm that the increase
in uPA-generated plasmin upon PAI-1 downregulation is respon-
sible for inducing apoptosis in HBMECs (Figure 3E). Because
plasmin has been shown to activate other proteases, in particular
MMP-3/stromelysin-1 (Nagase et al., 1990) and indirectly
Figure 3. uPA-Mediated Plasminogen Acti-
vation Induces EC Apoptosis
(A) Top: western blot analysis of cell-associated
(CA) and conditioned medium (CM)-secreted
uPA and CA uPAR in ECs transfected with siRNA
as indicated at top. rPAI-1 was added at 2.5 mg/
ml. Bottom: RT-PCR analysis of uPAR and b-actin
expression in cell extracts obtained in the same
conditions.
(B) The presence of uPA and uPAR at the surface
of cells treated as in (A) was examined by flow
cytometry. The data represent the means ± SD
of triplicate samples and are representative of
three experiments showing similar results.
(C) The proteolytic activity of uPA in CA and uPA
secreted in CM was determined by colorimetric
assay as described in Experimental Procedures.
The data represent the means ± SD of triplicate
samples.
(D) The presence of plasminogen (Plg) and plasmin
(Pln) secreted in CM and in cell extracts (CA) was
examined by casein zymography in the same
experimental conditions as in (A).
(E and F) The percentage of apoptotic cells in ECs
transfected with PAI-1 siRNA and control siRNA
and treated as indicated was determined by flow
cytometry. The data represent the means ± SD
of triplicate dishes and are representative of two separate experiments showing similar results. rPAI-1 was added at 2.5 mg /ml, aprotinin at 200 mg/ml, and
anti-uPA antibody or mouse IgG control at 7 mg/ml. AG3340 was added at 10 mg/ml.
*p < 0.05, **p < 0.01 for PAI-1 siRNA versus control siRNA in (B), (C), (E), and (F); #p < 0.01 for values versus PAI-1 siRNA in (E).
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conceivable that the effect of plasmin on apoptosis might be an
indirect effect of MMP activation by plasmin. To eliminate this
possibility, we performed experiments in the presence of an
MMP inhibitor (AG3340). The data indicate that treatment with
AG3340 does not prevent ECs from undergoing apoptosis
upon PAI-1 downregulation (Figure 3F), indicating that the effect
of plasmin on apoptosis is therefore MMP independent.
Increase in FasL-Mediated EC Apoptosis
in the Absence of PAI-1
Wenextdeterminedwhether theprotectiveeffectofPAI-1against
apoptosis involves interference with the intrinsic or the extrinsic
apoptotic pathway. In a first experiment, we examined the effect
of PAI-1 downregulation on the expression of phospho-Bcl-2,
Bcl-XL, Bak, and Bax and the activation of Akt and ERK1/2. This
analysis revealed no differences in the expression and/or activa-
tion of these proteins upon downregulation of PAI-1 by siRNA
(FigureS2). In contrast,weobservedan increase in cleavedactive
caspase-8 and in caspase-8 activity in the absence of activation
of caspase-9. This effect was suppressed by the addition of sta-
ble human rPAI-1. Altogether, these data suggest that in the ab-
sence of PAI-1, there is an activation of the extrinsic apoptotic
pathway in ECs. Considering the central role played by the Fas/
FasL pathway in EC apoptosis, we asked whether plasmin could
affect theactivity of Fas/FasL.Wefirst documented thatHBMECs
expressed Fas and FasL under unstimulated conditions (Fig-
ure 4A). The Fas receptorwas functional because the cells under-
went apoptosis when exposed to a recombinant soluble FasL
(sFasL) (Figures 4B and 4C). More direct evidence supporting
the involvement of FasL in HBMEC apoptosis upon downregula-
tion of PAI-1 was then obtained by demonstrating that blockingFas/FasL interaction with an anti-Fas antibody (ZB4) inhibited
apoptosis in HBMECs transfected with PAI-1 siRNA (Figure 4B)
whereasanonspecificmouse IgGhadnoeffect. In contrast, treat-
ment of SK-N-BE(2) neuroblastoma cells with sFasL did not
induce apoptosis (Figure 4C) because these cells did not consti-
tutively expressFasasdeterminedby fluorescence-activated cell
sorting (FACS) analysis (Figure 4D). In a second experiment, we
tested whether PAI-1 downregulation would induce apoptosis
in HBMECs in the absence of FasL. To accomplish this, we gen-
erated a FasL siRNA and first demonstrated that it inhibited the
expression of FasL in HBMECs by 65% (Figure 5A). We then
examined the effect of simultaneously downregulating PAI-1
andFasL inHBMECsbydual siRNA transfection. This experiment
(Figure 5B) indicated a significant reduction in the percentage of
apoptotic HBMECs when FasL was simultaneously downregu-
lated with PAI-1, but not when a control scrambled FasL siRNA
sequencewas used. Downregulation of FasL alone had no effect,
consistent with Fas/FasL having no effect on basal apoptosis but
having an effect on apoptosis in the absence of PAI-1. Consis-
tently, the cleavage of PARP observed upon transfection of ECs
with PAI-1 siRNA was significantly reduced upon simultaneous
transfection with a FasL siRNA, but not with a control scrambled
siRNA (Figure 5C). These data thus provide evidence that FasL is
a downstream target of PAI-1 and a necessary intermediate in the
induction of apoptosis in ECs uponPAI-1 downregulation. On the
basis of these observations, we postulated that the increase in
plasmin activity in the absence of PAI-1 might solubilize sFasL
and enhance Fas-dependent apoptosis.
Plasmin Cleaves FasL at Arg144-Lys145
This possibility was first tested by examining the proteolytic
activity of plasmin on a soluble recombinant glycosylated
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revealed a time-dependent cleavage of the 36 kDa FLAG-FasL in
the presence of plasmin and the generation of a cleavage prod-
uct with amolecular mass of approximately 21.5 kDa (Figure 6A).
This cleavage was inhibited by leupeptin. Neither uPA nor plas-
minogen cleaved FasL, but cleavage occurred in the presence
of both plasminogen and uPA and was blocked in the presence
of aprotinin, leupeptin, or rPAI-1 (Figure 6B). To identify the plas-
min cleavage site of FasL, the N-terminal amino acid sequence
of the 21.5 kDa FasL plasmin-generated fragment was deter-
mined by Edman degradation (Figure 6C; Figure S3A). This anal-
ysis revealed the N-terminal sequence Lys-Val-Ala-His-Leu-Thr,
indicating that there is a plasmin cleavage site in FasL at Arg144-
Lys145 in the trimerization domain, located in the extracellular
segment of the protein. This analysis predicted the release of a
soluble FasL fragment of 137 amino acids with a molecular
mass of 15.7 kDa (nonglycosylated) and higher pending the de-
gree of glycosylation. We next examined whether plasmin could
also cleave native membrane-associated FasL. For this experi-
ment, human HT1080 cells (which do not express FasL) were
transfected with a pcDNA plasmid containing either the full-
length sequence of wild-type (WT) FasL or the same sequence
in which the plasmin cleavage site Arg144-Lys145 was mutated
to Val144-Ala145 (mu FasL). To demonstrate that this mutation
did not affect the apoptotic activity of FasL, we cocultured WT
Figure 4. Increase in FasL-Mediated Apoptosis in the Absence of
PAI-1
(A) The expression of Fas and FasL in human brain microvascular ECs
(HBMECs) was determined by flow cytometry.
(B) The percentage of apoptotic cells in HBMECs transfected with siRNAs in
the absence or presence of an anti-Fas blocking antibody or rPAI-1 (2.5 mg/
ml) was determined by flow cytometry after staining with propidium iodide.
The data represent the means ± SD of triplicate samples.
(C) Apoptosis in HBMECs and SK-N-BE(2) tumor cells was determined by flow
cytometry as in (B) after the cells were treated for 24 hr with sFasL at the
indicated concentrations. The data represent the means ± SD of triplicate
samples.
(D) The expression of Fas in SK-N-BE(2) tumor cells was determined by flow
cytometry.
#p < 0.01, *p < 0.001 in (B) and (C).
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T cells and examined the effect on apoptosis in Jurkat T cells
(Cappellesso et al., 2000). This experiment (Figure S4) revealed
similar increases in apoptosis of Jurkat T cells in the presence
of either WT FasL- or mu FasL-expressing HT1080 cells. Thus,
the mutation at Arg144-Lys145 does not affect FasL apoptotic
activity. To demonstrate that the mutation affects the cleavage
of FasL, we subjectedmembrane extracts fromHT1080 cells ex-
pressing WT or mu FasL to plasmin digestion and examined the
extracts for the presence of FasL bywestern blot (Figure 6D). The
data indicated a loss of the 40 kDa membrane-associated FasL
protein and the presence of an 21.5 kDa fragment in HT1080
cells expressing WT FasL, but not in cells overexpressing mu
FasL. The data thus confirm that plasmin cleaves cell-associated
FasL at the specific Arg144-Lys145 site. To further demonstrate
that plasmin promotes the cleavage and release of FasL, we
performed a series of experiments in cultured HBMECs measur-
ing the amount of FasL released in the culture medium upon
exposure to plasmin. The data (Figure 6E) indicated an increase
in sFasL in themedium in the presence of plasmin at a concentra-
tion of 0.01 to 10 mg/ml that was inhibited by the addition of a2
anti-plasmin but not by the addition of an MMP inhibitor. This
is consistent with plasmin having a direct effect on releasing
sFasL from the surface of HBMECs that does not involve MMP
activation.
The 21.5 kDa Plasmin-Generated FasL Fragment
Is Released upon PAI-1 Downregulation
and Is Proapoptotic
Using immunoprecipitation, we next documented the presence
of the 21.5 kDa plasmin-generated FasL peptide in the condi-
tioned medium of HBMECs upon downregulation of PAI-1. Con-
sistent with our previous data, this fragment was detected in the
supernatant of HBMECs transfected with a PAI-1 siRNA but not
with the control siRNA or upon addition of rPAI-1 (Figure 7A).
Further evidence supporting a key role for the cleavage of
FasL by plasmin in increasing apoptosis in PAI-1-deficient ECs
was obtained by comparing the effect of PAI-1 downregulation
in HBMECs expressing either WT FasL or mu FasL. This experi-
ment (Figures 7B and 7C) indicated a significantly higher level of
apoptosis associated with an increased presence of cleaved
PARP in cells that overexpressed WT FasL and in which PAI-1
was downregulated. Such an increase, above the level of apo-
ptosis typically observed in ECs expressing endogenous FasL
and transfected with PAI-1 siRNA, was not observed in ECs
that overexpressed mu FasL. Under these conditions, the level
of apoptosis was similar to the level observed in cells expressing
endogenous FasL. Altogether, these data provide direct evi-
dence that plasmin cleaves membrane-associated FasL at
Arg144-Lys145 to release an 21.5 kDa soluble fragment in
the supernatant of HBMECs upon PAI-1 knockdown and that
apoptosis upon PAI-1 downregulation is dependent on the
release of sFasL.
To obtain confirmation that the soluble FasL fragment gener-
ated by plasmin is proapoptotic in HBMECs, we generated a
recombinant FasL fragment starting at Lys145 and containing
a 63His tag on its N terminus using the pRSET bacterial expres-
sion vector. This plasmid was transfected into competent BL21
E. coli, and the 63His-tagged protein (63HisLys145FasL) was
Figure 5. FasL Is Required for EC Apoptosis upon
PAI-1 Downregulation
(A) HBMECs were transfected with a scrambled (CTL) siRNA
sequence or a FasL siRNA and examined after 72 hr for the
presence of FasL in the cell lysate by western blot. A quantita-
tive analysis of the data obtained by scanning three separate
blots is shown in the lower panel. The data are the mean ratios
± SD of FasL/actin.
(B) HBMECs were transfected with FasL siRNA, PAI-1 siRNA,
or a combination of both siRNAs and their respective scram-
bled controls and examined after 72 hr for apoptosis by flow
cytometry. The data represent the mean numbers ± SD of ap-
optotic cells from triplicate samples. *p < 0.025, **p < 0.01,
#p < 0.005.
(C) Cell lysates of HBMECs treated as indicated were exam-
ined for PARP cleavage by western blot analysis.
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a nickel-chelating column by elution with 250mM imidazole (Fig-
ures S3B and S3C). A preparation containing 70 mg/ml of the pro-
tein was tested for its effect on EC apoptosis. The data indicated
that 63HisLys145FasL protein is a potent inducer of apoptosis in
HBMECs at concentrations ranging from 10 to 500 ng/ml and
that its proapoptotic activity is inhibited in the presence of an
anti-Fas blocking antibody (Figure 7D). This apoptotic effect
was confirmed by the detection of PARP cleavage products by
western blot analysis (Figure S3D). Altogether, these data are
consistent with PAI-1 having a protective effect against EC apo-
ptosis by inhibiting the release by plasmin of a sFasL fragment
that is an activator of caspase-8 and -3 in ECs. Because it has
been suggested that FasL needs to form a trimer to be active
and plasmin cleaves FasL in the trimerization domain, we exam-
inedwhether 63HisLys145FasL forms a trimer. FLAG-sFasL and
63HisLys145FasL were incubated with the crosslinking agent
disuccinimidyl suberate (DSS) and examined for trimer formation
by western blot (Figure S5A). The data showed that FLAG-sFasL
forms a trimer in the presence of DSS but that 63HisLys145FasL
does not, indicating that cleavage in the trimerization domain by
plasmin prevents trimer formation. However, we showed that
63HisLys145FasL is proapoptotic (Figure 7D). To confirm the
proapoptotic activity, we tested whether 63HisLys145FasL ac-
tivates Fas by examining the presence of Fas/FADD complexes
in lysates of HBMECs exposed to FLAG-sFasL or 63HisLys145-
FasL. This experiment (Figure S5B) indicated the presence of
FADD associated with Fas in HBMECs treated with FLAG-sFasL
and 63HisLys145FasL and thus confirms that 63HisLys145-
FasL is active in the absence of trimer formation.
PAI-1 Control of Angiogenesis In Vitro Is Fas Dependent
It was important to determine whether PAI-1’s control of angio-
genesis in vitro is FasL dependent. We therefore plated HBMECs
on Matrigel and examined the effect of PAI-1 downregulation on
the formation of a network of cords of ECs that mimic a vascular
network. The data (Figures 8A and 8B) revealed a significant in-
hibition in the number of branches in the network formed by
HBMECs in the presence of sFasL or when cells were trans-
fected with PAI-1 siRNA. The reduction in branching in HBMECstransfected with PAI-1 siRNA was markedly prevented in the
presence of rPAI-1, a blocking antibody against uPA, aprotinin,
or plasminogen-depleted serum. Consistent with the effect of
PAI-1 on angiogenesis being dependent on Fas/FasL, the addi-
tion of a blocking antibody against Fas also prevented the reduc-
tion in branching. These data are consistent with our data on
apoptosis and indicate that PAI-1 affects angiogenesis in vitro
by a mechanism that is Fas dependent.
Fas, FasL, uPA, and uPAR Are Expressed
in Neuroblastoma Tumors Orthotopically
Implanted in Mice
To obtain evidence that Fas/FasL and the plasminogen system
contribute to EC apoptosis in tumors, we examined by immuno-
fluorescence the expression of FasL, Fas, uPA, and uPAR in neu-
roblastoma tumors orthotopically implanted in mice. The data
(Figure S6) revealed a strong expression of uPAR in cells aligned
along the basement membrane (type IV collagen) of blood ves-
sels, consistent with uPAR being expressed in vascular ECs.
uPA also was coexpressed with PECAM-1/CD31-positive ECs
in the tumor vasculature. There was no obvious difference in
uPA and uPAR expression between tumors grown in WT mice
and PAI-1/ mice. We also demonstrated the coexpression of
PECAM-1/CD31 and Fas or PECAM-1/CD31 and FasL in vascu-
lar structures in these tumors (Figure S6). The data thus indicate
that Fas/FasL and uPA/uPAR are expressed in ECs in vivo. Al-
though the data do not demonstrate that they are responsible
for the increased apoptosis observed in the absence of PAI-1,
the selective expression of these proteins in vascular ECs in
tumors is consistent with their role in controlling EC apoptosis
in vivo.
In summary, our data identify a cleavage site for plasmin in
FasL that results in the release of a proapoptotic sFasL peptide
and provide a mechanism explaining the previously reported
proangiogenic activity of PAI-1 (Figure S7).
DISCUSSION
Our data provide amechanism explaining the protective effect of
PAI-1 against apoptosis through its control of the pericellular
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Plasmin Cleaves FasL and Induces ApoptosisFigure 6. Cleavage of Recombinant and
Membrane-Associated FasL by Plasmin
(A and B) Western blot analysis of FLAG-FasL
(10 mg/ml) treated in the conditions indicated at
the top using an anti-FLAG antibody (upper
panels) or an anti-FasL antibody (lower panels).
Concentrations used were as follows: leupeptin,
500 mg/ml; plasmin (Pln), 1 mg/ml; uPA, 600 IU/ml;
plasminogen (Plg), 1 mg/ml; aprotinin, 1 mg/ml;
rPAI-1, 50 mg/ml.
(C) Silver staining of a polyacrylamide gel of
recombinant sFasL incubated in the presence or
absence of Pln as indicated in (A) and (B).
(D) Western blot analysis with an anti-FasL anti-
body of membrane proteins extracted from
HT1080 cells expressing wild-type (WT) FasL or
a mutant (mu) FasL and incubated for 1 hr in the
presence or absence of plasmin (1 mg/500 mg of
lysate) at 37C before SDS-PAGE.
(E) Levels of sFasL in serum-free culture medium
of HBMECs incubated in the presence of plasmin
and inhibitors as indicated. a2 anti-plasmin was
added at a concentration of 100 mg/ml and
AG3340 at a concentration of 10 mg/ml. The data
represent the mean concentrations ± SD of sFasL
in the culture medium of triplicate samples and are
representative of two experiments showing similar
results. *p < 0.025, **p < 0.01, ***p < 0.005 versus
untreated cells; #p < 0.005 versus plasmin-treated
cells; NS, not significant.activity of plasmin and FasL solubilization. Evidence for such
a FasL-dependent mechanism is provided by the following
data: (1) induction of apoptosis in PAI-1-deficient ECs is blocked
in the presence of an anti-Fas antibody; (2) PAI-1-deficient ECs
do not undergo apoptosis in the absence of FasL; (3) there is
no additional increase in apoptosis in PAI-1-deficient ECs over-
expressing FasL in which the plasmin cleavage sequence has
beenmutated; and (4) FasL is released as a 21.5 kDa soluble pro-
tein in the culture medium of ECs upon PAI-1 downregulation or
plasmin treatment. We also report a cleavage site in FasL that is
sensitive to plasmin. Membrane-associated FasL (mFasL) is
typically solubilized by MMPs, and its cleavage by plasmin has
not been reported thus far.
The effect of sFasL on apoptosis is complex, differs among cell
types, and is in part governed by cell polarity. In nonpolarized
cells like hematopoietic and mesenchymal cells and lympho-
cytes, the solubilization of FasL results in Fas inactivation (Tanaka
et al., 1995). In contrast, in polarized epithelial cells, sFasL is
active and induces apoptosis (Powell et al., 1999). The cleavage
of mFasL by MMP-7 in prostate epithelial cells induces
Figure 7. The 21.5 kDa Plasmin-Generated FasL
Fragment Is Proapoptotic
(A) The presence of the 21.5 kDa sFasL plasmin-generated
fragment was detected by immunoprecipitation and western
blot analysis with an anti-FasL antibody in the conditionedme-
dium of HBMECs treated as indicated at top.
(B) HBMECs were transfected with a pcDNA plasmid contain-
ing either WT FasL or mu FasL. Stable transfected cells were
selected and retransfected with a PAI-1 siRNA or a control
siRNA and tested for apoptosis by FACS analysis after 72 hr.
The data represent the means ± SD of triplicate samples.
*p < 0.05.
(C) Cells treated as described in (B) were examined for the
presence of cleaved PARP by western blot analysis.
(D) The recombinant 63HisLys145FasL protein that corre-
sponds to the 21.5 kDa plasmin-generated FasL fragment
obtained as shown in Figure S2C was added at the indicated
concentrations to HBMECs for 48 hr, and the percentage of
apoptotic cells was measured by flow cytometry. An
anti-Fas antibody (ZB4) was added at 500 ng/ml. The data
represent the means ± SD of triplicate samples. **p < 0.005.
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Plasmin Cleaves FasL and Induces ApoptosisFas-mediated apoptosis (Vargo-Gogola et al., 2002), whereas it
protects tumor cells from drug cytotoxicity (Mitsiades et al.,
2001). In ECs under hypoxia, FasL is solubilized by MMPs and
forms a 70 kDa trimeric complex that inhibits Fas and prevents
hypoxia-induced apoptosis (Mogi et al., 2001). Our data are dif-
ferent, as we report here the cleavage of FasL not by an MMP
but by plasmin and demonstrate that this cleavage enhances
rather than prevents apoptosis in ECs. Because plasmin is
a known activator of several MMPs, it was important to demon-
strate that the effect of plasmin on the solubilization of sFasL
and apoptosis in vivo was also a direct effect as shown in a test
tube assay. Our data demonstrating an absence of effect of
AG3340 on the release of sFasL by plasmin in cultured HBMECs
and on HBMEC apoptosis upon PAI-1 downregulation are con-
sistent with plasmin having a direct effect independent of MMP
activation. The cleavage of FasL by plasmin was demonstrated
not only for a recombinant protein but also for FasL expressed
byHT1080cells. Theabsenceof cleavage in cells overexpressing
mu FasL also confirms the specificity of the cleavage. It is inter-
esting to note that in the case of MMP-7, two cleavage sites
have been reported. A primary cleavage site at a leucine residue
in the sequence ELAELR between the transmembrane domain
and the self-assembly (trimerization) domain generates a 25
kDa fragment, and a secondary ELR site in the self-assembly
domain generates an approximately 21 kDa fragment. In the
case of plasmin, the cleavage sitewas identified close to the sec-
ondary MMP-7 cleavage site at RK in the KELRKV sequence in
the self-assembly domain and generated a 21.5 kDa fragment.
Consistent with the plasmin cleavage site being within the trime-
rizationdomain,wedemonstratedanabsenceof trimer formation
in the recombinant 63HisLys145FasL protein corresponding to
the plasmin-generated sFasL. However, we demonstrated that
this fragment is proapoptotic in ECs and activates Fas. These
data are also consistent with the observation of Vargo-Gogola
et al. (2002) that MMP-7, which also cleaves FasL in its trimeriza-
tion domain, increases apoptosis in prostate epithelial cells and
indicate that trimerization of sFasL is not necessary for its activity.
Thismay explainwhy our results differ from the data ofMogi et al.
(2001). Although these authors did not identify theMMPcleavage
site in FasL, they reported the presence of soluble FasL trimers
that prevented Fas-mediated apoptosis. It is thus conceivable
Figure 8. FasL Inhibits EC Branching in
Matrigel
(A) Representative photomicrographs of HBMECs
plated on Matrigel and treated as indicated. Scale
bars = 400 mm.
(B) Quantitative analysis of the data in (A). The data
represent the mean numbers of branches per mi-
croscopic field ± SD from a total of six fields exam-
ined in each of three different dishes. *p < 0.001,
#p < 0.001.
that the absence of the trimerization do-
main in the case of cleavage by plasmin
(and MMP-7) may be responsible for the
proapoptotic activity of sFasL.
The demonstration that plasmin
cleaves FasL in vitro does not necessarily
mean that plasmin also cleaves FasL in vivo, as plasmin is in-
hibited in vivo by a series of physiological inhibitors other that
PAI-1, such as a2 anti-plasmin. Although a2 anti-plasmin primar-
ily acts on the fibrinolytic system inside the vasculature, it is pres-
ent in the extravascular space that is invaded by sprouting ECs
during angiogenesis and could inhibit the release of sFasL by
plasmin as suggested by our in vitro data (Figure 6E). However,
PAI-1 may play a more predominant role because it is made by
ECs and controls pericellular plasmin activity. The question of
the role of PAI-1 as the only regulator of angiogenesis remains
open. Nevertheless, our data showing an increase in apoptosis
in ECs in PAI-1 null mice indicate that PAI-1 has a contributory
function.
The central role of Fas/FasL in controlling EC apoptosis and
angiogenesis is well recognized. Although quiescent ECs ex-
press low levels of Fas, they become increasingly sensitized to
Fas-mediated apoptosis under hypoxic conditions or when stim-
ulated by VEGF or TNFa (Sata andWalsh, 1998), and attachment
of ECs to ECM proteins is a known mechanism that protects
these cells from Fas-mediated apoptosis. Hypoxia and VEGF
have been shown to upregulatePAI-1 expression in ECs (Dimova
and Kietzmann, 2006), which raises the possibility that upregula-
tion of PAI-1 under hypoxia or by VEGF could be critical for the
survival of stimulated ECs. This hypothesis is currently being
explored in our laboratory.
The protective role of PAI-1 against EC apoptosis could also
be critical for conditions other than tumor angiogenesis. For
example, it has been demonstrated that PAI-1 inhibits apoptosis
in vascular smooth muscle cells during the formation of athero-
sclerotic plaques. When mice that are deficient in apolipoprotein
E (ApoE/) and show increased formation of atherosclerotic
plaques are crossed with PAI-1-deficient mice, there is a de-
crease in plaque formation that corresponds to an increase in
apoptosis in vascular smooth muscle cells (Luttun et al., 2002).
Our data suggest that in the absence of plasminogen/plasmin,
there would be a stimulation of angiogenesis and wound healing.
This is not necessarily the case, however, as there is an impair-
ment in wound healing in plasminogen (Plg)-deficient mice
(Kortlever and Bernards, 2006) and an acceleration in PAI-1-de-
ficient mice (Chan et al., 2001). However, a critical feature in
these models is the presence of a provisional fibrin matrix, as
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gen and fibrinogen there is a stimulation rather than inhibition of
wound healing (Bugge et al., 1996). Our studies have not ad-
dressed the effect of PAI-1 deficiency on fibrin and have focused
on pericellular plasmin activity and its local control over the
release of cell surface-associated proteins like FasL. Although
the formation of a provisional fibrin matrix is critical in wound
healing, its role in tumor angiogenesis is less well understood.
It is conceivable that the selective presence of PAI-1 stabilized
by vitronectin in the pericellular space is a mechanism allowing
plasmin to act remotely to degrade the provisional fibrin matrix
without solubilizing FasL at the surface of ECs. These possibili-
ties clearly deserve further investigation. Our data demonstrating
a significant delay in angiogenesis in the absence of host-de-
rived PAI-1 provide important insight into vascular diseases
other than tumor angiogenesis. Whether PAI-1 could be a
valuable target in controlling angiogenesis is an interesting but
presently unanswered question that is currently being examined
in our laboratory.
EXPERIMENTAL PROCEDURES
Orthotopic Tumor Model
PAI-1-deficient mice (PAI-1/) and their corresponding wild-type mice (PAI-
1+/+) on a mixed genetic background of 87% C57BL/6 and 13% 129 strain
(Carmeliet et al., 1993) were mated with Rag-1-deficient mice (Rag-1/: B6;
129 s-Rag-1tm/Mom/J) purchased from Charles River Laboratories (L’Arbresle,
France) to generate PAI-1/ and PAI-1+/+ Rag-1/ immunodeficient mice.
Mice were anesthetized with avertin, and a 1 mm3 SK-N-BE(2) cl10 subcuta-
neous tumor fragment was sown on the left adrenal gland as described previ-
ously (Chantrain et al., 2004). Mice were sacrificed between 3 and 9 weeks
after tumor implantation. Ex vivo angiographies and analysis of tumors were
performed as described previously (Chantrain et al., 2004) (see Supplemental
Experimental Procedures). All animal experiments were performed in accor-
dance with procedures established by the Institutional Animal Care and Usage
Committee of Childrens Hospital Los Angeles under approved protocol
#41-05.
RNA Interference
A first siRNA duplex with sequences corresponding to nucleotides 457–477 of
human PAI-1 cDNA (GenBank accession number X12701) (50-AAGGACGAG
ATCAGCACCACA-30) was used for most experiments. A second nucleotide
sequence corresponding to nucleotides 286–306 of human PAI-1 cDNA (50-AA
CGTGGTTTTCTCACCCTAT-30) was used to confirm the effect ofPAI-1 knock-
down on apoptosis in HBMECs. The siRNA sequence for FasL was 50-AACT
GGGCTGTACTTTGTATA-30 (Ji et al., 2005). All siRNA duplex oligonucleotides
were synthesized by QIAGEN Sciences. HBMECs were transfected over 5 hr
with 40 nMPAI-1 siRNA, FasL siRNA, or a corresponding scrambled siRNA us-
ing either Lipofectamine 2000 (Invitrogen) or a TransMessenger Transfection
Kit (QIAGEN Sciences). FITC-labeled siRNA was used to assess transfection
efficiency.
Measurement of PAI-1 and sFasL Levels
PAI-1 and sFasL levels were determined using commercially available ELISA
kits for human PAI-1 (American Diagnostica Inc.) and human sFasL (R&D Sys-
tems). The amount of protein in each sample was determined using a BCA
protein assay kit (Pierce), and PAI-1 values were corrected for the amount of
protein present in each sample.
Apoptosis
To evaluate apoptosis in HBMECs in culture, we used a TUNEL APO-Direct kit
(BD Biosciences PharMingen) or flow cytometry analysis of cells labeled with
propidium iodide (5 mg/ml). After nonadherent cells were washed with PBS,
adherent cells were harvested using trypsin-EDTA, resuspended in medium
containing serum, collected by centrifugation, and resuspended with nonad-
332 Cancer Cell 14, 324–334, October 7, 2008 ª2008 Elsevier Inc.herent cells in 1 ml of 1% paraformaldehyde in PBS. After several washes
with PBS, the cells were resuspended in 70% ethanol and stored at 20C
prior to staining and analysis by flow cytometry.
Flow Cytometry
Analysis of HBMECs by flow cytometry was performed using the following pri-
mary antibodies: mouse monoclonal antibody against human uPA (American
Diagnostica Inc.), mouse monoclonal antibody against human uPAR (Ameri-
can Diagnostica Inc.), mouse monoclonal antibody against Fas (Alexis), and
mouse monoclonal antibody against FasL (Alexis). FITC-conjugated horse
anti-mouse IgG (Vector Laboratories) was used as a secondary antibody. Cells
were analyzed on a Beckman Coulter Epics ESP cell sorter equipped with
a 488 nm argon laser. Data were acquired and analyzed with EXPO32 software
(Applied Cytometry Systems).
Caspase-3, -8, and -9 Activities
Caspase-3 and -8 activities were measured using the ApoTarget Caspase-3/
CPP32 and Caspase-8/FLICE Colorimetric Protease Assay (BioSource). The
activity of each caspase was determined in 200 mg of cell lysate proteins
suspended in 50 ml of extraction buffer. Absorbance at 405 nmusing a spectro-
photometer was determined after 24 hr of incubation with the substrate for
each caspase. The presence of cleaved caspase-8 and -9 was examined by
western blot analysis using antibodies from Cell Signaling Technology.
uPA Proteolytic Activity
Ten microliter aliquots of conditioned media or cell extracts were incubated
with bovine plasminogen (Sigma, 0.1 mg/ml) and a chromogenic substrate
for plasmin (Spectrozyme PL; 0.5 mM; American Diagnostica Inc.) in PBS.
Reactions (100 ml) were carried out in the presence or absence of amiloride
(2 mM) in 96-well microtitration plates at room temperature for 20 min, and
the release of free p-nitroaniline from the chromogenic substrate was mea-
sured spectrophotometrically. The activity was determined in reference to
a standard curve generated by the activity of a two-chain uPA standard, cor-
rected for the amount of protein in each sample and expressed in international
units (IU) per mg of proteins.
Zymographic Analysis of Plasmin Generation
a-casein (1 mg/ml; ICN Biomedicals) was incorporated in 0.1% SDS/8% poly-
acrylamide gels. Aliquots of conditioned media and cell extracts containing
equal amounts of proteins were mixed with loading buffer (10% SDS, 4%
sucrose, 0.25 M Tris-HCl [pH 6.8], 0.1% bromophenol blue). After electropho-
resis, SDS was eluted from the gels by two washes (30 min each) of 100 mM
glycine, 2.5% Triton X-100 buffer (pH 8.0). Gels were incubated overnight at
37C in 100 mM glycine buffer (pH 8.0), stained with 0.1% Coomassie brilliant
blue, and destained in 20% methanol/10% acetic acid.
Mutagenesis of FasL
The amino acid substitutions Arg144/Val144 and Lys145/Ala145 were
introduced in the plasmin cleavage site of FasL using a QuikChange Site-
Directed Mutagenesis Kit (Stratagene) according to the manufacturer’s in-
structions and a human FasL cDNA subcloned into BamHI pcDNA 3.1-Neo
(Invitrogen) expression vector (Vargo-Gogola et al., 2002) kindly provided by
L. Matrisian (Vanderbilt University). For the substitution, we used the primer
pair forward 50-CCTGAAAAAAAGGAGCTGGTGGCAGTGGCCCATTTAACAG
GC-30; reverse 50-GCCTGTTAAATGGGCCACTGCCACCAGCTCCTTTTTTTC
AGG-30.
Matrigel Angiogenic Assay
Matrigel (Becton Dickinson) was added at 300 ml to each well of a 24-well plate
and allowed to polymerize for 1 hr at 37C. HBMECs (4 3 104) in culture
medium were then added to the coated wells. Cells were incubated for 24 hr
at 37C, viewed under an Olympus CKX41 microscope, and photographed
using PictureFrame 2.1 software (Optronics). The numbers of branches were
counted in five different fields in triplicate wells.
Statistical Evaluation
Results are represented as mean ± standard deviation (SD). For in vivo data,
statistical analysis was performed using a nonparametric Mann-Whitney U
Cancer Cell
Plasmin Cleaves FasL and Induces Apoptosistest. In vitro experiments were performed in triplicate and repeated at least two
times, and the analysis was performed using a two-tailed Student’s t test.
p% 0.05 was considered statistically significant.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures,
Supplemental References, and seven figures and can be found with this article
online at http://www.cancercell.org/cgi/content/full/14/4/324/DC1/.
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